ImmuneBridge
San Francisco, US · Delaware corporation · 2 known investors
ImmuneBridge develops a platform for manufacturing cell therapies using umbilical cord blood stem cells, incorporating ML-powered donor screening and proprietary stem cell expansion technology. The platform serves biotech developers and academic institutions seeking to produce scalable, safe, and cost-effective cell therapies across diverse immune lineages.
AI & Machine LearningBiotechMedical Devices
Founders & leadership
AJ
Alicia JacksonDirector
SA
Stuart Alexander JacobsonExecutive Officer, Director
CZ
Cheryl ZimberlinDirector
GA
Gregory A. BonfiglioDirector
PP
Peretz PartenskyExecutive Officer, Director
MK
Mary Kim WarrenDirector
NH
Nina Horowitz
RT
Rui Tostoes
DM
Dylan MorrisDirector
NI
Nadiya IshnazarovaDirector
OA
Omri Amirav-DroryDirector
TF
Thomas FarrellDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$5.6MraisedApr 2025 · 6 investors · BiotechnologyRule 506(b)
▶$5.6MraisedApr 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dylan MorrisDirector
- Nadiya IshnazarovaDirector
- Omri Amirav-DroryDirector
- Alicia JacksonDirector
- Stuart Alexander JacobsonExecutive Officer, Director
- Thomas FarrellDirector
- Offering amount
- $7.1M
- Amount sold
- $5.6M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$10.2MraisedJan 2023 · 15 investors · BiotechnologyRule 506(b)
▶$10.2MraisedJan 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alicia JacksonDirector
- Cheryl ZimberlinDirector
- Gregory A. BonfiglioDirector
- Peretz PartenskyExecutive Officer, Director
- Dylan MorrisDirector
- Mary Kim WarrenDirector
- Offering amount
- $14.2M
- Amount sold
- $10.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.